Arrowhead Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Good morning and thank you for joining us on day 3 of the 47th Annual Goldman Sachs Global Healthcare Conference. I'm Paul Choi, and I cover this mid-cap biotech sector here at the firm. It's our pleasure to have Arrowhead Pharmaceuticals here for our first session today.
But before we begin, I'm required to make certain disclosures. These disclosures relate to investment banking and other relationships that we may have with companies discussed here today. I'm prepared to read out loud these disclosures to you. However, these disclosures are available to you as clients of the firm on our research portal.
But otherwise, we'll go ahead and start. To my immediate left is Vincent Anzalone, who -- with Arrowhead, and we also have to my far left, Daniel Apel, who is CFO. What we'll do is turn it over to Vince, maybe to give some high-level comments on the company's strategic priorities for the remainder of 2026 and going into 2027, and then we'll go to Q&A. Any questions along the way in the audience, please feel free to raise your hand and we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
